The Radiofrequency ablation devices market is rapidly growing, thanks to Boston Scientific Corporation's launch of DIRECTSENSE technology to monitor the effects of ablation procedures.

 

Radiofrequency ablation is a moderately new strategy for diminishing agony related with back torment. In a new audit distributed by an association that reviews clinical developments, the Global Commission on Systemic Palliative Care (GCSPC) expressed that the most well-known application for radiofrequency removal is the treatment of torment in the spine, which has been utilized since the 1970s. There are numerous different applications, albeit these are two instances of the commonplace kind of agony that this gadget is utilized to mitigate.

Rising prevalence of cancer is expected to drive growth of the global radiofrequency ablation devices market during the forecast period. The number of cancer cases has increased over the years globally. According to the World Health Organization (WHO), in 2018, around 18.1 million new cases of cancer and 9.6 million deaths due to cancer were reported globally. According to the same source, around 70% of deaths from cancer occur in emerging economies with lung cancer accounting for the majority of deaths followed by breast cancer. Furthermore, according to the National Cancer Institute, in 2020, around 1,806,590 new cases of cancer are expected to be diagnosed in the U.S. with over 600,000 people dying from this disease. Such high incidence of cancer has led to increased demand for radiofrequency ablation devices. Hence, these factors are expected to drive growth global radiofrequency ablation device market during the forecast period. Furthermore, rising prevalence of cardiovascular disease combined with increasing number of ablation procedures is expected to boost the global radiofrequency ablation device market growth over the forecast period.